Merck sues U.S. government over Medicare negotiation; Biogen board and C-suite are in step on M&A potential

Taking stock of the drug industry, from the lab to the medicine chest

June 6, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Gerry Broome/AP STAT+ | FDA will allow troubled chemotherapy maker to resume distribution of cancer drugs in short supply The FDA will allow troubled a chemotherapy maker to resume distribution of drugs in short supply, with strict requirements. By Ed Silverman 'Tantamount to extortion': Merck sues U.S. government over Medicare negotiation program Merck on Tuesday sued to stop the federal government from implementing a new Medicare drug price negotiation program. By Rachel Cohrs and Ed Silverman STAT+ | FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer's advisory panel In April, the FDA approved Weisman as a voting member due to his "extensive experience and background in Alzheimer's disease." By Ed Silverman STAT+ | Medicare taps acting official to head up its new drug price negotiations Medicare has chosen a career official to temporarily lead its implementation of Democrats' drug pricing law. By Rachel Cohrs STAT+ | Biogen board and C-suite are in step as they eye M&A opportunities, new CEO says Biogen CEO Chris Viehbacher noted that dour markets have left many companies short on cash and looking for M&A opportunities. By Allison DeAngelis STAT+ | Biotech's trade secrets face growing threat from foreign influences, science leaders warn Concern about trade secrets raise thorny questions about the balance between conducting collaborative science and protecting IP. By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser